ClinicalTrials.gg
Not yet recruitingNCT07655089APOSTMUpdated Jun 17, 2026

Assessment of Post Operative Swelling Among Patients Following Extraction of Impacted Third Molars

An interventional study of Ward's Incision and Comma Incision in Post Operative Swelling, sponsored by College of Physicians and Surgeons Pakistan. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by College of Physicians and Surgeons Pakistan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized controlled trial aims to compare Ward's incision and Comma incision regarding postoperative swelling following extraction of impacted mandibular third molars. Secondary outcomes include pain and bleeding assessed 48 hours after surgery. The findings will help identify the incision technique associated with better postoperative outcomes

02

Conditions studied

  • Post Operative Swelling

Keywords

  • Impacted Mandibular Third Molar
  • Swelling,
  • Oral Surgery
03

In context

Lead sponsor

College of Physicians and Surgeons Pakistan is the lead sponsor of 15 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Patients aged 18-50 years. Male and female patients. Patients undergoing extraction of impacted mandibular third molars irrespective of angulation as evaluated radiographically.

Patients with no periodontal pathology related to the involved tooth on clinical examination.

-

Exclusion Criteria:

  • Patients with congenital or acquired bleeding disorders. Patients with any bony lesion adjacent to the impacted third molar. Medically patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Ward's Incision Group

    Standard Ward's incision with mucoperiosteal flap elevation for extraction of impacted mandibular third molar.

    Procedure: Ward's Incision · Procedure: Comma Incision

  • Active comparator
    Comma Incision Group

    Comma incision flap design for extraction of impacted mandibular third molar.

    Procedure: Ward's Incision · Procedure: Comma Incision

Interventions

  • ProcedureWard's Incision

    Patients allocated to Group A will undergo extraction of impacted mandibular third molars using Ward's incision. Depending on the degree of impaction, a sulcular incision will be made from the mesiobuccal aspect of the first or second molar extending distally. A relieving incision will be placed mesially without severing the interdental papilla, followed by a distal releasing incision on the mandibular ramus. A full-thickness mucoperiosteal flap will then be elevated to facilitate tooth extraction.

  • ProcedureComma Incision

    Patients allocated to Group B will undergo extraction of impacted mandibular third molars using the Comma incision technique. The incision will begin below the second molar and extend to its distobuccal line angle, then curve smoothly upward to the gingival crest. The incision will continue as a crevicular incision around the distal aspect of the second molar. A distolingually based flap will be elevated to provide adequate exposure for extraction of the impacted third molar.

06

What researchers measure

Primary outcomes

  1. Postoperative Swelling

    Degree of postoperative swelling assessed using a Visual Analog Scale (VAS) ranging from 0 to 5, where 0 indicates no swelling and 5 indicates extremely severe swelling following extraction of impacted mandibular third molars

    Time frame: 48 hours after surgery

  2. Postoperative Swelling

    Degree of postoperative swelling assessed 48 hours after extraction of impacted mandibular third molars using a Visual Analog Scale (VAS) ranging from 0 to 5, where 0 indicates no swelling and 5 indicates extremely severe swelling.

    Time frame: 48 hours after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sayed N, Bakathir A, Pasha M, Al-Sudairy S. Complications of Third Molar Extraction: A retrospective study from a tertiary healthcare centre in Oman. Sultan Qaboos Univ Med J. 2019 Aug;19(3):e230-e235. doi: 10.18295/squmj.2019.19.03.009. Epub 2019 Nov 5. PubMed 31728221 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Aug 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2026
First posted
Jun 17, 2026
StartEst.
Jul 5, 2026
Primary completionEst.
Aug 5, 2026
CompletionEst.
Aug 5, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07655089
Lead sponsor
College of Physicians and Surgeons Pakistan
Responsible party
Faiz ur rahman (Principal investigator, Department of Operative Dentistry, College of Physicians and Surgeons Pakistan) — Principal investigator
First posted
Jun 17, 2026
Start date
Jul 5, 2026 (estimated)
Primary completion
Aug 5, 2026 (estimated)
Completion
Aug 5, 2026 (estimated)
Last update
Jun 17, 2026

Study contacts

Fatima Khattak Khattak
Contact
fatimakhattak32@gmail.com
03315125534

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion